UPPER GASTROINTESTINAL SAFETY WITH THE BUFFERED SOLUTION OF ALENDRONATE 70 MG: POST-MARKETING EXPERIENCE

被引：0
|
作者：
Hruska, J. [1 ]
Jorgensen, F. K. [2 ]
Pierleoni-Nielsen, C. [2 ]
Eriksen, E. F. [3 ]
机构：
[1] McDACom GmbH, Zurich, Switzerland
[2] Klifo AS, Glostrup, Denmark
[3] Oslo Univ Hosp, Dept Clin Endocrinol, Oslo, Norway
来源：
OSTEOPOROSIS INTERNATIONAL | 2017年 / 28卷
关键词：
OSTEOPOROSIS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P589
引用
收藏
页码：S366 / S366
页数：1
相关论文
共 50 条
  • [1] UPPER GASTROINTESTINAL SAFETY WITH THE BUFFERED SOLUTION OF ALENDRONATE 70 MG: 6 YEARS OF POST-MARKETING EXPERIENCE
    Fardellone, P.
    Boezennec, B.
    Cortet, B.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S483 - S484
  • [2] Upper Gastrointestinal Safety with the Buffered Solution of Alendronate 70mg: Postmarketing Experience.
    Hruska, Josef
    Jorgensen, Flemming Kjaer
    Eriksen, Erik Fink
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S269 - S269
  • [3] PERSISTENCE WITH THE BUFFERED SOLUTION OF ALENDRONATE 70 MG: PROSPECTIVE OBSERVATIONAL STUDY
    Giusti, A.
    Bianchi, G.
    Barone, A.
    Hruska, J.
    Black, D. M.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S431 - S431
  • [4] Post-marketing Safety Experience with Vedolizumab: Malignancy
    Bhayat, Fatima
    Blake, Aimee
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S313 - S314
  • [5] Persistence with Buffered Solution of Alendronate 70mg: Prospective Observational Study
    Giusti, Andrea
    Black, Dennis M.
    Barone, Antonella
    Hruska, Josef
    Bianchi, Gerolamo
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 174 - 175
  • [6] A Prospective Open-Label Observational Study Of a Buffered Soluble 70 mg Alendronate Effervescent Tablet On Upper Gastrointestinal Safety and Medication Errors: the GastroPASS Study
    Minisola, Salvatore
    Vargas, Antonio Ponce
    Mauro, Giulia Letizia
    Madurga, Fernando Bonet
    Adami, Giovanni
    Black, Dennis M.
    Qizilbash, Nawab
    Blanch-Rubio, Josep
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 311 - 311
  • [7] A Prospective Open-Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study
    Minisola, Salvatore
    Vargas, Antonio P.
    Mauro, Giulia Letizia
    Madurga, Fernando Bonet
    Adami, Giovanni
    Black, Dennis M.
    Qizilbash, Nawab
    Blanch-Rubio, Josep
    JBMR PLUS, 2021, 5 (07)
  • [8] Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience
    Welch, KMA
    CEPHALALGIA, 2001, 21 : 25 - 28
  • [9] Vedolizumab clinical and post-marketing safety experience of opportunistic infections
    Ng, S. C.
    Palo, W.
    Blake, A.
    Rana-Khan, Q.
    Bhayat, F.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S41 - S41
  • [10] VEDOLIZUMAB CLINICAL AND POST-MARKETING SAFETY EXPERIENCE OF OPPORTUNISTIC INFECTIONS
    Ng, Siew C.
    Palo, William
    Blake, Aimee
    Rana-Khan, Qasim
    Bhayat, Fatima
    GASTROENTEROLOGY, 2017, 152 (05) : S575 - S576
12345